ERBB2 and breast cancer: In ER-positive, HER2-negative BC patients, PMRT, administered in 65% of patients (68% in those ≤50 years and 62.5% in those >50 years), was more often considered in an increasing burden of SLN metastases and in patients submitted to a cALND.